1,722,082 research outputs found
Johnson, Peter - Emancipation Index Record
No full textEmancipation index record of Johnson, Peter aged 66 yrs in 1846; certificate number (#595)
Johnson, Peter, 3/400017
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/428102Surname: Johnson. Given Name(s) or Initials: Peter. Military Service Number or Last Known Location: 3/400017. Prisoner of War Enquiry Card Index Number: K/15. Division Enquiry: Vic. Rank: T/CPL. Unit: 3rd Battalion Korea326859
Item: [2016.0049.60364] "Johnson, Peter, 3/400017
Alien Registration- Johnson, Peter (Portland, Cumberland County)
Full text linkhttps://digitalmaine.com/alien_docs/31257/thumbnail.jp
Development of multiphoton label-free super-resolution microscopy techniques for biomedical imaging
No full textBiology exists across a range of spatial scales from whole organisms (up to ~25 m) down to individual molecules (<1 nm). Optical microscopy has allowed the study of many biological processes at scales that are not resolvable by the human eye (~< 100 μm). However, due to diffraction, the resolution of an optical microscope at visible wavelengths is ~200 nm, prohibiting the study of biological processes below this limit. A group of techniques developed to overcome this limit called super-resolution techniques, have improved the resolution to ~1-10 nm. However, these super-resolution techniques require fluorescent labelling of biological samples limiting their applicability especially to live cell or long term imaging. Multiphoton label-free imaging techniques do not require labelling of the sample but are still limited by diffraction. In this work two methods of label-free super-resolution with multiphoton imaging are established and explored. A physical method employing the photonic nanojet (PNJ) phenomenon is used to improve the resolution of second harmonic generation (SHG) microscopy. Optimal imaging parameters are established alongside developments in sample preparation and imaging workflow to maximise imaging performance. The limit of resolution is established and found to be 125 nm a 2.7 x improvement over the diffraction limit for SHG excited at 800 nm. The method is used to detect ultrastructural changes in fibrillar collagen in lung disease unobservable under diffraction-limited imaging. The method is used further to characterise other extracellular matrix proteins such as elastin, revealing new biophysical insight. A computational method based on signal fluctuations is also developed for application to cellular autofluorescence signals. Resolution improvement was demonstrated for widefield fluorescence and point-scanning imaging systems. A 3D model sample was refined and lightsheet imaging employed to facilitate multiphoton imaging. The method is used to image mitochondria using the autofluorescence from the metabolic co-enzymes nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD). This thesis successfully implements label-free super-resolution using multiple methods and imaging modalities. These tools have led to new biological understanding; moreover, they are simple to implement allowing for widespread use and application to disease research
The composition of R. G. Collingwood's The New Leviathan
No full textCollingwood's The New Leviathan is a difficult text. It comprises philosophy, political theory, political opinion and history in what is sometimes an uneasy amalgam. Despite its being the culmination of thirty years of work in ethics and political theory, the final text was clearly affected by the adverse circumstances under which it was written, these largely being Collingwood's illness which increasingly affected his ability to work as the writing of The New Leviathan progressed. This paper seeks to disentangle the composition of the book thereby shedding light on its distinctive character as the last substantial piece of philosophical work published in Collingwood's lifetime.</p
Optimizing therapy in advanced stage Hodgkin Lymphoma
No full textThe treatment of Hodgkin Lymphoma has evolved continuously since the introduction of extended-field radiotherapy in the 1960s to involved-field then involved-node radiotherapy, multi-agent chemotherapy, combined chemo-radiotherapy, risk-adapted and response-adapted modulation, and most recently, introduction of antibody-drug conjugates and immune checkpoint-blocking antibodies. These changes have translated into progressively increasing cure rates, so that 10-year survival figures now exceed 80%, compared to less than 50% 40 years ago. The challenge now is how to improve upon success while maintaining, or if possible improving, the quality of life for survivors. Steering between under-treatment, with the risk of avoidable recurrences, and over-treatment, with the risk of unnecessary toxicity, remains complex since control of the lymphoma and the probability of survival are no longer closely linked. This requires trials with long follow-up and continuous re-appraisal of the interaction between the illness; the method used to define risk, and the type of treatment involved. One important factor in this is age: outcomes in older patients have not improved at the same rate as those in the population under 60, reflecting the need for different approaches. Recently, treatment has moved from being primarily risk-based, using baseline characteristics such as anatomical stage and severity of the illness, to a more dynamic approach which takes account of the response to therapy, using functional imaging to make an early appraisal, with the option to modulate subsequent treatment. The results of several trials indicate that this has advantages, but that a combination of risk- and response-adaptation is probably ideal
Lymphoma: turning biology into cures
No full textDiffuse large B-cell lymphoma (DLBCL) is the commonest aggressive non-Hodgkin lymphoma with approximately 5,000 cases annually in the UK. The R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) regimen has become the international standard of care with cure rates of around 75% and despite extensive studies aimed at improving the outcomes, R-CHOP has not been superseded. Those patients that do not respond to R-CHOP have a poor outlook. DLBCL is a disease with marked molecular heterogeneity; advances in gene expression profiling and mutational analysis can be used to increase our understanding of the disease and identify new therapeutic targets. Precision medicine using new agents, including small molecule inhibitors, is now being investigated for DLBCL. Progress in this disease is likely to come by targeting heterogeneous subtypes through novel combinations. Where R-CHOP fails, we hope that these new approaches can succeed by providing personalised medicine using precision diagnostics to guide new treatment paradigms
- …
